Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Kianzad (Amsterdam, Netherlands), F. De Man (Amsterdam, Netherlands), L. Celant (Amsterdam, Netherlands), A. Vonk Noordegraaf (Amsterdam, Netherlands), L. Handoko (Amsterdam, Netherlands), H. Bogaard (Amsterdam, Netherlands). Precapillary pulmonary hypertension in patients with a high HFpEF probability: Insights from the Amsterdam UMC PAH-cohort. 1516

Member's Comments

No comment yet.

Related content which might interest you:

• Noninvasive evaluation of pulmonary artery pressure during exercise: the importance of right atrial hypertension
• The updated treatment algorithm in PAH
• Who to treat/who not to treat: the "non group I" PH patients